SCHEMBL22896565

SCHEMBL22896565

NC(=O)C(=O)C(Cc1cccs1)NC(=O)c1nscc1-c1ccccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.42
▸ CAPN1 P07384 10/20 0.42
▸ RAB9A P51151 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ ESR1 P03372 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ STAT3 P40763 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ ESR2 Q92731 1/20 0.36
▸ CTSS P25774 1/20 0.35
▸ HPGDS O60760 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HSPA1A P0DMV8 1/20 0.35
▸ HSPA5 P11021 1/20 0.35
▸ HSPA9 P38646 1/20 0.35
▸ HSPA2 P54652 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22897038 0.87 CAPN1 (0.47) CAPN1CTSS
SCHEMBL22897005 0.86 CAPN1 (0.53) CAPN1CTSS
SCHEMBL22897149 0.86 CAPN1 (0.42) CAPN1KMT2ACTSSLMNA
SCHEMBL22896146 0.86 USP30 (0.40) USP30CAPN1RAB9AESR1POLB
SCHEMBL22896515 0.86 CAPN1 (0.49) USP30CAPN1RAB9ACTSS
SCHEMBL22896806 0.85 CAPN1 (0.44) CAPN1CTSS
SCHEMBL22896755 0.84 CAPN1 (0.41) CAPN1MEN1KMT2APOLBSMN1; SMN2
SCHEMBL22896324 0.84 CAPN1 (0.42) USP30CAPN1RAB9AESR1POLB
SCHEMBL22897178 0.84 CAPN1 (0.44) USP30CAPN1RAB9ACTSS
SCHEMBL22897154 0.83 CAPN1 (0.43) CAPN1CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 — — US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 — — US disclosed
US-10894776-B2 — — 2021-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 USP30 748/4885CAPN1 3/4885RAB9A 2461/4885
US-10894776-B2 — CAPNS1, CAPN9, CAPN2 USP30 531/4885CAPN1 4/4885RAB9A 2055/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 USP30 748/4885CAPN1 3/4885RAB9A 2461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback